Eslam Elkhadrawy/LinkedIn
Jan 28, 2026, 11:45
Eslam Elkhadrawy on Heparin-Induced Thrombocytopenia
Eslam Elkhadrawy, Product Specialist at Inspire Pharma Egypt, shared on LinkedIn:
”Heparin-Induced Thrombocytopenia (HIT):
When anticoagulation paradoxically causes thrombosis
HIT is a severe immune-mediated adverse drug reaction in which heparin exposure leads to thrombocytopenia accompanied by a high risk of thrombosis, rather than bleeding.
The condition is driven by IgG antibodies against the heparin–platelet factor 4 (PF4) complex, resulting in platelet activation and excessive thrombin generation.
Key message:
In HIT, thrombocytopenia reflects platelet activation and consumption, not impaired hemostasis.
References
Greinacher A. NEJM, 2015
Warkentin TE. Circulation, 2015”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 17:36Paul Whiteley: Neurodevelopmental and Autism Risks in Fetal and Neonatal Alloimmune Thrombocytopenia
-
Jun 24, 2026, 17:22Kavitha Dev: A Low Platelet Count Isn’t Always Critical, But It Should Never Be Ignored
-
Jun 24, 2026, 17:04Recurrent Cervical Internal Carotid Vasospasm Linked to Autosomal Recessive PTGIS Defect – International Journal of Stroke
-
Jun 24, 2026, 16:49Gaurav Kharya: Bridging the Gap in Safe Blood Access for Patients Who Can’t Wait
-
Jun 24, 2026, 16:40William Wallace: Vitamin C and Collagen Work as One Biological System
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc